Home › Kanser sa Atay (Hepatocellular Carcinoma) › Pennsylvania › Pittsburgh
Pag-aaral pangklinika para sa Kanser sa Atay (Hepatocellular Carcinoma) sa Pittsburgh, PA
Isang pag-aaral para sa Kanser sa Atay (Hepatocellular Carcinoma) ang naghahanap ng mga kalahok sa isang site sa loob o malapit sa Pittsburgh. Buksan ito upang makita kung sino ang makakasali at kung paano makipag-ugnayan sa koponan ng pag-aaral.
Opisyal na teksto ng pag-aaral (English)
A Phase 1 Study of the Safety and Tolerability of CTX-10726
Nagre-recruitPhase 1
- UPMC Hillman Cancer Center, Pittsburgh
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
Nagre-recruitPhase 1
- Exelixis Clinical Site #32, Pittsburgh
A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
Nagre-recruitPhase 1/2
- Upmc Hillman Cancer Center(Univ of Pittsburgh), Pittsburgh
Testing the Addition of an Anti-cancer Drug, Sapanisertib, to the Usual Chemotherapy Treatment (Cabozantinib) in Metastatic Liver Cell Cancer With a Change in Genes for the Protein β-Catenin, The SAPHIRE Trial
Nagre-recruitPhase 1/2
- UPMC Hillman Cancer Center, Pittsburgh
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
Nagre-recruitPhase 3
- Research Site, Pittsburgh
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Nagre-recruitPhase 1/2
- Children's Hospital of Pittsburgh of UPMC, Pittsburgh
FOG-001 in Locally Advanced or Metastatic Solid Tumors
Nagre-recruitPhase 1/2
- University of Pittsburgh Medical Center, Hillman Cancer Center, Pittsburgh
Molecular Basis of Pediatric Liver Cancer
Nagre-recruitObservasyonal na pag-aaral
- UPMC Children's Hospital of Pittsburgh, Pittsburgh
Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer
Nagre-recruitPhase 2
- Allegheny General Hospital, Pittsburgh
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
Nagre-recruitPhase 2
- UPMC Hillman Cancer Center, Pittsburgh
A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma
Nagre-recruitPhase 1
- Clinical Trial Site, Pittsburgh
Patient Preference for Subcutaneous vs. Intravenous Immune Therapy
Nagre-recruitPhase 2
- UPMC Hillman Cancer Center, Pittsburgh
Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC
Nagre-recruitPhase 2
- UPMC Hillman Cancer Center, Pittsburgh
Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies
Nagre-recruitPhase 1/2
- UPMC Hillman Cancer Center, Pittsburgh
Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA)
Nagre-recruitPhase 2
- UPMC Hillman Cancer Center, Pittsburgh
Pag-aaral para sa Kanser sa Atay (Hepatocellular Carcinoma) sa ibang lungsod
- Houston, TX31 pag-aaral
- New York City, NY24 pag-aaral
- Dallas, TX19 pag-aaral
- Los Angeles, CA19 pag-aaral
- Boston, MA18 pag-aaral
- Cleveland, OH18 pag-aaral
- Philadelphia, PA16 pag-aaral
- Chicago, IL16 pag-aaral
- San Francisco, CA14 pag-aaral
- Orange, CA14 pag-aaral
- Jacksonville, FL14 pag-aaral
- San Antonio, TX13 pag-aaral
Iba pang pag-aaral sa Pittsburgh
- Non-Small Cell Lung Cancer48 pag-aaral
- Kanser (lahat ng uri)41 pag-aaral
- Kanser sa Suso39 pag-aaral
- Colorectal Cancer32 pag-aaral
- Metastatic Cancer31 pag-aaral
- Melanoma31 pag-aaral
- Kanser sa Ovary30 pag-aaral
- Kanser ng Endometrium23 pag-aaral
- Kanser sa Prostate23 pag-aaral
- Kanser sa Baga23 pag-aaral
- Squamous Cell Carcinoma ng Ulo at Leeg22 pag-aaral
- Stroke22 pag-aaral
Mula sa ClinicalTrials.gov, na-kuha noong Okt 6, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.